Gracell Biotechnologies Inc.
GRCLNASDAQHealthcare
$10.25
+$0.01(+0.05%)
Market Cap$197973420
P/E Ratio—
52W High$10.435
52W Low$1.4
Gracell Biotechnologies Inc. (GRCL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GRCL · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 11, 2024EPS Actual
-$0.30
Est. -$0.14 · -114.3%
Revenue
—
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 11, 2024
After Market Close
▼ Miss EPS
GRCL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 12, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 13, 2024 | — | — | — | — | — | — |
| ▼ Q1 FY2024 | Mar 11, 2024 | -$0.14 | -$0.30 | -114.3% | — | — | — |
| ▲ Q4 FY2023 | Nov 13, 2023 | -$0.26 | -$0.10 | +61.5% | — | — | — |
| ▲ Q3 FY2023 | Aug 14, 2023 | -$0.37 | -$0.30 | +18.9% | — | — | — |
| — Q2 FY2023 | May 15, 2023 | -$0.35 | -$0.35 | +0.0% | — | — | — |
| ▲ Q1 FY2023 | Mar 13, 2023 | -$0.43 | -$0.30 | +30.2% | — | $0.00B | — |
| ▼ Q4 FY2022 | Nov 14, 2022 | -$0.09 | -$0.36 | -300.0% | — | $0.00B | — |
Q3 FY2024
Aug 12, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 13, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 11, 2024Miss
EPS Actual
-$0.30
EPS Est.
-$0.14
EPS Surpr.
-114.3%
Revenue
—
Q4 FY2023
Nov 13, 2023Beat
EPS Actual
-$0.10
EPS Est.
-$0.26
EPS Surpr.
+61.5%
Revenue
—
Q3 FY2023
Aug 14, 2023Beat
EPS Actual
-$0.30
EPS Est.
-$0.37
EPS Surpr.
+18.9%
Revenue
—
Q2 FY2023
May 15, 2023
EPS Actual
-$0.35
EPS Est.
-$0.35
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2023
Mar 13, 2023Beat
EPS Actual
-$0.30
EPS Est.
-$0.43
EPS Surpr.
+30.2%
Revenue
—
Q4 FY2022
Nov 14, 2022Miss
EPS Actual
-$0.36
EPS Est.
-$0.09
EPS Surpr.
-300.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.87 | $1.54 | $0.98 | 0 |
| Q2 FY2024 | $1.63 | $1.34 | $0.86 | 0 |
| Q1 FY2024 | $1.91 | $1.58 | $1.01 | 2 |
| Q4 FY2023 | $-0.30 | $-0.27 | $-0.25 | 3 |
| Q3 FY2023 | $-0.30 | $-0.28 | $-0.20 | 3 |
| Q2 FY2023 | $-0.45 | $-0.37 | $-0.24 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 10 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 10 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 10 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 10 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 10 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 18 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Mar 11, 2024 | -114.3% | $10.25 | — | — |
| ▲ Q4 FY2023 | Nov 13, 2023 | +61.5% | $4.40 | $4.59 | +4.32% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +18.9% | $3.84 | $3.89 | +1.30% |
| ▲ Q2 FY2023 | May 15, 2023 | +0.0% | $2.04 | $2.23 | +9.31% |
| ▲ Q1 FY2023 | Mar 13, 2023 | +30.2% | $1.86 | $1.81 | -2.96% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -300.0% | $3.75 | $3.79 | +1.07% |
| ▼ Q3 FY2022 | Aug 15, 2022 | -300.0% | $3.38 | $3.38 | +0.00% |
| ▼ Q2 FY2022 | May 16, 2022 | -362.5% | $3.33 | $3.43 | +3.00% |
Q1 FY2024—
Report Date
Mar 11, 2024
EPS Beat/Miss
-114.3%
Price Before
$10.25
Price After
—
Q4 FY2023+4.32%
Report Date
Nov 13, 2023
EPS Beat/Miss
+61.5%
Price Before
$4.40
Price After
$4.59
Q3 FY2023+1.30%
Report Date
Aug 14, 2023
EPS Beat/Miss
+18.9%
Price Before
$3.84
Price After
$3.89
Q2 FY2023+9.31%
Report Date
May 15, 2023
EPS Beat/Miss
+0.0%
Price Before
$2.04
Price After
$2.23
Q1 FY2023-2.96%
Report Date
Mar 13, 2023
EPS Beat/Miss
+30.2%
Price Before
$1.86
Price After
$1.81
Q4 FY2022+1.07%
Report Date
Nov 14, 2022
EPS Beat/Miss
-300.0%
Price Before
$3.75
Price After
$3.79
Q3 FY2022+0.00%
Report Date
Aug 15, 2022
EPS Beat/Miss
-300.0%
Price Before
$3.38
Price After
$3.38
Q2 FY2022+3.00%
Report Date
May 16, 2022
EPS Beat/Miss
-362.5%
Price Before
$3.33
Price After
$3.43
Avg Beat Reaction+2.99%
Avg Miss Reaction+1.36%
Beat Rate4 / 8 quarters
Largest Move+9.31% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GRCL ends December
Gracell Biotechnologies Inc. (GRCL) most recently reported earnings on March 11, 2024 for Q1 FY2024, posting EPS of $-0.30 — missing the analyst consensus of $-0.14 by -114.3%. The next GRCL earnings date is expected around September 1, 2026.
Each quarter, investors track GRCL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GRCL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GRCL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GRCL earnings · 5 questionsGracell Biotechnologies Inc.'s next earnings report is expected around September 1, 2026. GRCL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GRCL historically reports after market close (AMC).
GRCL earnings datewhen is GRCL earningsGRCL next earnings datewhen does GRCL report earningsGRCL earnings calendar
▸ Source: FMP · Gracell Biotechnologies Inc. SEC filings · US GAAP · Gracell Biotechnologies Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026